Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3IPSX)

• Drug Name: ATLCAR.CD30.CCR4 cells Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Immune System disease	4A01-4B41	Phase 1	[1]
Immunoproliferative disorder	2B32	Phase 1	[1]
Lymphatic disease	BD9Z	Phase 1	[1]
Lymphoma	2A80-2A86	Phase 1	[1]
Neoplasm	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DM3IPSX

Molecule-Related Drug Atlas

Drug(s) Targeting C-C chemokine receptor type 4 (CCR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mogamulizumab	DMISH0Z	Mycosis fungoides	2B01	Approved	[2]
RPT193	DMZJ0N3	Asthma	CA23	Phase 2	[3]
FLX475	DMI7S39	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
GSK-2239633	DMUNVXR	Asthma	CA23	Phase 1	[5]
AZD-1678	DMY7R3X	Asthma	CA23	Preclinical	[6]
N-(4-tert-butylthiazol-2-yl)-1H-indol-4-amine	DMFUBQ8	Discovery agent	N.A.	Investigative	[7]
AT-008	DMODLPS	Autoimmune diabetes	5A10	Investigative	[5]
4-tert-butyl-N-phenylthiazol-2-amine	DM5CPBK	Discovery agent	N.A.	Investigative	[7]
4-methyl-N-(naphthalen-1-yl)thiazol-2-amine	DMFRASQ	Discovery agent	N.A.	Investigative	[7]
4-tert-butyl-N-(naphthalen-1-yl)oxazol-2-amine	DM5U6ZW	Discovery agent	N.A.	Investigative	[7]

Drug(s) Targeting Lymphocyte activation antigen CD30 (TNFRSF8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brentuximab vedotin	DMWLC57	Hodgkin lymphoma	2B30	Approved	[8]
AFM13	DMN45IC	Hodgkin lymphoma	2B30	Phase 2	[9]
Iratumumab	DMI874B	Lymphoma	2A80-2A86	Phase 2	[10]
SGN-30	DMJ9M5D	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]
CAR-T cells targeting CD30	DML0KWM	Non-hodgkin lymphoma	2B33.5	Phase 2	[12]
CAR-T cells targeting CD30	DML0KWM	Non-hodgkin lymphoma	2B33.5	Phase 2	[13]
TT11X	DMW3M7X	Hodgkin lymphoma	2B30	Phase 2	[14]
TT20X	DMHGI09	Aggressive cancer	2A00-2F9Z	Phase 2	[14]
4SCAR19 and 4SCAR30	DMUYFS1	B-cell lymphoma	2A86	Phase 1/2	[15]
Anti-CD30 CAR T cells	DM8139V	Lymphoma	2A80-2A86	Phase 1/2	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 4 (CCR4)	TT7HQD0	CCR4_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]
Lymphocyte activation antigen CD30 (TNFRSF8)	TT2GM5R	TNR8_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]

References

• [1] ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL
• [2] Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010 Dec;12(6):770-9.
• [3] ClinicalTrials.gov (NCT05399368) A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 as Monotherapy in Adults With Moderate-to-Severe Atopic Dermatitis. U.S.National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 61).
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030818)
• [7] Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3.
• [8] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [9] Clinical pipeline report, company report or official report of Affimed Therapeutics.
• [10] Utilizing CD30 expression as a rational target for therapy of lymphoma. J Hematol Oncol. 2012; 5(Suppl 1): A2.
• [11] The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002 Jul 1;62(13):3736-42.
• [12] ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
• [13] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [14] Clinical pipeline report, company report or official report of Tessa Therapeutics
• [15] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [16] ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)